ZNF692 and adrenal cortex carcinoma: The results presented in Figure 2B indicated a significant association between ZNF692 and unfavorable progression-free survival (PFS) in several cancer types, including ACC (p = 0.0015), CESC (p = 0.0303), KIRC (p = 0.0486), LIHC (p = 0.0040), PRAD (p = 0.0003), READ (p = 0.0387), and UCEC (p = 0.0219).